🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

48 results for “Ascend” Clear

  1. Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin, Lonapegsomatropin

    Ascendis Pharma Endocrinology Division A/S

    Turner Syndrome (TS), idiopathic short stature (ISS), short stature homeobox containing gene deficiency (SHOX-D), small for gestational age (SGA)

    phase 3 small molecule active

    1 trial

  2. XEOMIN 200 unités, poudre pour solution injectable, Placebo of Xeomin 200 U

    Pari Pharma GmbH

    Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)

    phase 3 small molecule active

    1 trial

  3. Yorvipath 420 micrograms/1.4 mL solution for injection in pre‑filled pen, Yorvipath 168 micrograms/0.56 mL solution for injection in pre-filled pen, Yorvipath 294 micrograms/0.98 mL solution for injection in pre‑filled pen

    Ascendis Pharma Bone Diseases A/S

    Chronic hypoparathyroidism

    phase 3 small molecule active

    1 trial

  4. A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

    uniQure biopharma B.V.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 other active

    1 trial

  5. A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) (ACHIEVE)

    Pharm Research Associates (UK) Limited

    Congenital Hyperinsulinism (CHI)

    phase 2 other active

    1 trial

  6. A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People with Cystic Fibrosis

    Arcturus Therapeutics Holdings

    Cystic Fibrosis

    phase 2 other active

    1 trial

  7. STK-001 - Single Ascending Doses

    Stoke Therapeutics

    Dravet Syndrome

    phase 2 small molecule completed

    1 trial

  8. TransCon PTH

    Ascendis Pharma Bone Diseases A/S

    Hypoparathyroidism (HP) in Adults

    phase 2 small molecule active

    1 trial

  9. A First-in-Human, randomised, double blind, placebo-controlled, single ascending dose trial to evaluate safety, tolerability, and pharmacokinetics of APC148 in healthy adults.

    Pharma Mar S.A.

    Urinary tract infections (UTIs)/complicated UTI (cUTI)

    phase 1 other active

    1 trial

  10. A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants

    Merck Sharp and Dohme

    Amyotrophic lateral sclerosis and Alzheimer’s disease

    phase 1 other active

    1 trial

  11. A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ASCENDING, SINGLE-DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF RAY121 IN HEALTHY VOLUNTEERS

    Pharma Mar S.A.

    Nervous System disease

    phase 1 other active

    1 trial

  12. A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease

    Novartis Ophthalmics Europe

    Chronic Kidney Disease

    phase 1 other active

    1 trial

  13. A Single Ascending Dose, Single-Centre Study, to Assess Pharmacokinetics, Safety and Tolerability of a Single Intramuscular Dose of Bedaquiline Long-Acting Injection Formulation in Healthy Participants

    Janssen-Cilag International N.V.

    Tuberculosis

    phase 1 other active

    1 trial

  14. A Single-Ascending-Dose Study of MK6916 in Healthy Participants

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial

  15. A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis

    Roche Registration Limited

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  16. A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis

    Roche Registration Limited

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  17. A first-in-human, randomized, double-blind, placebo-controlled, three-part study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of BP1.15205 after single and repeated oral ascending doses, including the BP1.15205 effect on cardiac repolarization, as well as an exploratory assessment of the food effect on the pharmacokinetics of BP1.15205 in healthy participants

    Bioprojet Pharma

    Narcolepsy

    phase 1 other active

    1 trial

  18. A first-in-human, randomized, participant and investigator blinded, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of HJB647 in healthy participants and otherwise healthy participants with elevated blood pressure, with an open-label CYP3A inhibitor drug-drug interaction part

    Novartis Ophthalmics Europe

    Heart failure (HF)

    phase 1 other active

    1 trial

  19. A phase 1, randomised, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics in healthy adult subjects after subcutaneous injection of TISA-818-Inj-5mg/mL.

    Pharma Mar S.A.

    Idiopathic pulmonary fibrosis

    phase 1 other active

    1 trial

  20. A phase Ib, open-label, ascending dose study to assess safety, tolerability and pharmacokinetics of PIT565 in participants with rheumatoid arthritis (RA)

    Novartis Ophthalmics Europe

    Rheumatoid Arthritis

    phase 1 other active

    1 trial

  21. A phase Ib, open-label, ascending dose study with step-up doses to assess safety, tolerability, and pharmacokinetics of PIT565 in participants with systemic lupus erythematosus (SLE)

    Novartis Ophthalmics Europe

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  22. A randomized, single-center, double-blind, placebo-controlled, first-in-human trial with single and multiple ascending doses to determine safety, tolerability, and pharmacokinetics of GRT7040 in healthy volunteers

    Gruenenthal GmbH

    Treatment of pain

    phase 1 other active

    1 trial

  23. A single and multiple ascending dose study of topical ladarixin ophthalmic solution in healthy volunteers

    Dompe' Farmaceutici S.p.A.

    Ocular inflammatory conditions

    phase 1 other active

    1 trial

  24. A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).

    Agomab Therapeutics NV

    liver cirrhosis

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources